The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Abstract

Original languageEnglish
Pages (from-to)1105-1110
Number of pages6
JournalHaematologica
Volume111
Issue number3
DOIs
Publication statusE-pub ahead of print - 2 Oct 2025

Fingerprint

Dive into the research topics of 'The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology'. Together they form a unique fingerprint.

Cite this